Source: International Congress 2019 – Granulomatous disorders: from bench to bedside
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
M. Rossides (Stockholm, Sweden), S. Kullberg (Stockholm, Sweden), A. Eklund (Stockholm, Sweden), J. Grunewald (Stockholm, Sweden), E. Arkema (Stockholm, Sweden). Serious infections in sarcoidosis and the effect of treatment. 5160

Member's Comments

No comment yet.

Related content which might interest you: Secondary pulmonary mycoses etiology agent species diversity in patients with tuberculosis and in patients with HIV infection Source: Virtual Congress 2020 – Mechanism or pathways of chronic lung diseases Year: 2020 The comparison of the manifestation of systemic inflammation in patients with minor forms of tuberculosis and pulmonary sarcoidosis Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009 Non-tuberculous infections in patients with TNF-alpha-antagonist treatment Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Non-tuberculous infections in patients with anti-TNF treatment Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 The incidence of pulmonary infection caused by atypical pathogens in non-HIV immunocompromised patients Source: Annual Congress 2010 - Unusual pathogens in respiratory infections Year: 2010 The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 The impact of patients‘ age and concomitant diseases on community-acquired pneumonia outcome Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003 Effectiveness of treatment and correction of side effects in pulmonary MDR/XDR TB patients with concomitant liver injury Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017 The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Clinical characteristics and treatment response of pulmonary cryptococcosis in HIV negative patients Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections Year: 2009 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 The role of inflammatory parameters in the diagnosis and management of patients with community-acquired pneumonia Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function Source: Eur Respir J, 55 (3) 1901692; 10.1183/13993003.01692-2019 Year: 2020 Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 The role of viral and bacterial infections in asthma severity Source: Annual Congress 2005 - PG3 - Asthma: natural history, risk factors and overall management Year: 2005